TIDMFAB

RNS Number : 6758S

Fusion Antibodies PLC

17 November 2021

Fusion Antibodies plc

("Fusion" or the "Company")

Notice of results

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces it will release its unaudited interim results for the six months ended 30 September 2021 on Monday, 6 December 2021.

Fusion will host an online live presentation open to all investors on Thursday, 9 December at 11.00am, delivered by Dr Richard Jones, CEO and James Fair, CFO. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on its results whilst additionally providing an update on the business and current trading.

The presentation will be hosted through the digital platform Investor Meet Company.

Investors can sign up to Investor Meet Company for free and add to meet Fusion Antibodies plc via the following link: https://www.investormeetcompany.com/fusion-antibodies-plc/register-investor

For those investors who have already registered and added to meet the Company, they will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

Enquiries:

 
 Fusion Antibodies plc                                    www.fusionantibodies.com 
 Richard Jones, Chief Executive Officer                            Via Walbrook PR 
  James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                       Tel: +44 (0)20 3328 
                                                                              5656 
 James Reeve / Vivek Bhardwaj (Corporate 
  Finance) 
  Tony Quirke (Sales and Corporate Broking) 
 
 Walbrook PR                   Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                  Mob: +44 (0)7876 741 
                                                                               001 
 Paul McManus                                                 Mob: +44 (0)7980 541 
                                                                               893

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFIFEALELDLIL

(END) Dow Jones Newswires

November 17, 2021 05:00 ET (10:00 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Fusion Antibodies Charts.
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Fusion Antibodies Charts.